ClinicalTrials.gg
RecruitingNCT07576790EMBO-PROTECTUpdated Nov 10, 2026

Evaluation of Balloon Guide Catheter as Proximal Protection During Carotid Artery Stenting (EMBO-PROTECT)

An interventional study of balloon guide catheter and No Proximal Protection Group in Carotid Artery Stenosis (Symptomatic and Asymptomatic), sponsored by Instituto de Investigación Marqués de Valdecilla. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Instituto de Investigación Marqués de Valdecilla · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 10, 2026Now RecruitingFirst site in Spain+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Carotid Stenosis with a site in Spain — 1 open to participants now, 3 under way, none of them phase 3. Carotid Stenosis · Spain.

Started
2026
the only one that year
No phase
4 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Instituto de Investigación Marqués de Valdecilla

Among the 11 studies in Carotid Stenosis with a site in Spain, this one is the only one that started in 2026, is one of 4 with no phase, and was the 11th registered.

Carotid Stenosis

369 studies on the registry are indexed under Carotid Stenosis; 88 are open to participants now.

Browse Carotid Stenosis studies →

Open to participants now

1 of the 11 studies in Carotid Stenosis with a site in Spain is open now.

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 62 Carotid Stenosis studies recruiting now, 39 (63%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Carotid Stenosis with a site in Spain, or all of them as a file.
02

Study summary

Carotid angioplasty and stenting (CAS) is an effective treatment for carotid artery stenosis but carries a risk of cerebral embolization. This prospective randomized study evaluates the safety and efficacy of proximal embolic protection using a balloon guide catheter during CAS by comparing the incidence of diffusion-weighted MRI-detected microembolisms and symptomatic thromboembolic events between protected and unprotected procedures.

03

Conditions studied

  • Carotid Artery Stenosis (Symptomatic and Asymptomatic)

Browse trials for

Keywords

  • Carotid stenosis
  • Carotid artery stenting
  • Balloon guide catheter
  • Proximal embolic protection
  • Cerebral microembolism
  • Diffusion-weighted MRI
  • Stroke prevention
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Symptomatic or asymptomatic carotid artery stenosis
  • Candidate for carotid artery stenting
  • Written provided

Exclusion criteria

Exclusion Criteria:

  • Vascular anatomy unsuitable for balloon guide catheter placement
  • Severe renal failure
  • Previous disabling stroke or symptomatic intracranial hemorrhage
  • Evidence of carotid thrombus
  • Severe common carotid artery lesion
  • Chronic atrial fibrillation on oral anticoagulation
  • Acute coronary syndrome within 30 days
  • to anticoagulant or antiplatelet therapy
  • Contraindications to MRI
  • Contrast media allergy
  • Lack of prior dual antiplatelet therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    carotid artery stenting with proximal embolic protection using a balloon guide catheter

    Device: balloon guide catheter

  • Active comparator
    ratio to carotid artery stenting without proximal embolic protection using a balloon guide catheter.

    Other: No Proximal Protection Group

Interventions

  • Deviceballoon guide catheter

    Carotid artery stenting with proximal embolic protection using a balloon guide catheter.

  • OtherNo Proximal Protection Group

    Carotid artery stenting without proximal embolic protection

06

What researchers measure

Primary outcomes

  1. Incidence, number, and volume of new cerebral ischemic lesions detected by diffusion-weighted MRI within 48 hours after carotid artery stenting

    Time frame: Within 48 hours after the procedure

Secondary outcomes

  1. Incidence of symptomatic thromboembolic events (stroke or transient ischemic attack) within 30 days

    Time frame: During the procedure and within 30 days after the intervention

  2. Incidence of myocardial infarction or death within 30 days

    Time frame: 30days

  3. Technical success of carotid artery stenting procedure

    Technical success defined as successful deployment of the stent with residual stenosis \<30% and restoration of adequate blood flow without the need for conversion to another technique.

    Time frame: 30days

  4. Correlation between DW-MRI findings and clinical outcomes

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

Of 51 non-industry interventional studies with no phase under Carotid Stenosis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 50. This study's planned 12 months is below that.

Counting every sponsor, half of 62 studies reached it within 27 months; a quarter within 19 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
May 8, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 10, 2026
Sites
1 site added — first site in Spain
Show site
  • Hospital Universitario Marqués de Valdecilla · Santander, Spain
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Spain
    Show site
    • Hospital Universitario Marqués de Valdecilla · Santander, Spain
    + 1 other change: date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07576790
Lead sponsor
Instituto de Investigación Marqués de Valdecilla
Responsible party
Sponsor
First posted
May 8, 2026
Start date
Jul 1, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 10, 2026

Study contacts

veronica vidal
Contact
veronica.vidal@idival.org
942203389
lucia lavin
Contact
lucia.lavin@idival.org

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion